Prospects and RISC score of viral gene therapy for sarcoma.
Soft tissue sarcomas are a challenge for medical oncology and gene therapy. Protective and sensitising approaches that target normal and malignant tissue, respectively, both have their role for opening the therapeutic window. Recent data show that an intensive maintenance chemotherapy significantly reduces metastatic spread and improves disease-free survival in selected patient groups. However, delays of treatment due to cytopenia are frequent. Cytostatic drug resistance gene transfer to haematopoietic progenitor cells using retroviral vectors may allow further improvement of therapy results. In recent years, retroviral vector design, transduction techniques and engraftment capability of transduced cells have been optimised. Safety considerations of retroviral gene transfer have attracted public attention and can be addressed by analysis of genomic vector integration sites. A data bank project, 'retroviral insertion estimate of chromosomal integration' (RISC), containing > 200 integration sequences, has been set up by the authors' group to recognise critical genomic regions and genes involved with possible transforming capacity. Monitoring these parameters will allow the selection of the most suitable vectors for clinical application. Sarcoma cells seem to be highly susceptible to a variety of vectors, such as recombinant adeno-associated virus-2 (rAAV-2) vectors, adenoviral vectors or oncolytic herpes simplex viruses. Results from the first clinical trials with adenoviral vectors encoding for cytokines are promising. The other systems await further development towards clinical applications. Perspectives for further research are discussed in this review.
Fruehauf
S
S
Department of Internal Medicine V, University of Heidelberg, Hospitalstr. 3, 69115 Heidelberg, Germany. Stefan_Fruehauf@med.uni-heidelberg.de
Veldwijk
M R
MR
Zeller
W J
WJ
Laufs
S
S
D000818:Animals; D002875:Chromosomes / Q000648:ultrastructure; D003131:Combined Modality Therapy; D000229:Dependovirus / Q000235:genetics; D018572:Disease-Free Survival; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008954:Models, Biological; D008957:Models, Genetic; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D012306:Risk; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*; D014158:Transcription, Genetic
D019853:O(6)-Methylguanine-DNA Methyltransferase